HEADER CHAPERONE 10-MAY-11 2YI7 TITLE STRUCTURAL CHARACTERIZATION OF 5-ARYL-4-(5-SUBSTITUTED-2-4- TITLE 2 DIHYDROXYPHENYL)-1,2,3-THIADIAZOLE HSP90 INHIBITORS. COMPND MOL_ID: 1; COMPND 2 MOLECULE: HEAT SHOCK PROTEIN HSP 90-ALPHA; COMPND 3 CHAIN: A; COMPND 4 FRAGMENT: N-TERMINAL DOMAIN, RESIDUES 1-229; COMPND 5 SYNONYM: HSP90, HEAT SHOCK 86 KDA, HSP 86, HSP86, RENAL CARCINOMA COMPND 6 ANTIGEN NY-REN-38; COMPND 7 ENGINEERED: YES SOURCE MOL_ID: 1; SOURCE 2 ORGANISM_SCIENTIFIC: HOMO SAPIENS; SOURCE 3 ORGANISM_COMMON: HUMAN; SOURCE 4 ORGANISM_TAXID: 9606; SOURCE 5 EXPRESSION_SYSTEM: ESCHERICHIA COLI; SOURCE 6 EXPRESSION_SYSTEM_TAXID: 562 KEYWDS CHAPERONE, ATPASE EXPDTA X-RAY DIFFRACTION AUTHOR S.M.ROE,C.PRODROMOU,L.H.PEARL REVDAT 2 26-SEP-12 2YI7 1 JRNL REVDAT 1 16-MAY-12 2YI7 0 JRNL AUTH S.Y.SHARP,S.M.ROE,E.KAZLAUSKAS,I.CIKOTIENE,P.WORKMAN, JRNL AUTH 2 D.MATULIS,C.PRODROMOU JRNL TITL CO-CRYSTALIZATION AND IN VITRO BIOLOGICAL CHARACTERIZATION JRNL TITL 2 OF 5-ARYL-4-(5-SUBSTITUTED-2-4-DIHYDROXYPHENYL)-1,2,3- JRNL TITL 3 THIADIAZOLE HSP90 INHIBITORS. JRNL REF PLOS ONE V. 7E44642 2012 JRNL REFN ISSN 1932-6203 JRNL PMID 22984537 JRNL DOI 10.1371/JOURNAL.PONE.0044642 REMARK 2 REMARK 2 RESOLUTION. 1.40 ANGSTROMS. REMARK 3 REMARK 3 REFINEMENT. REMARK 3 PROGRAM : REFMAC 5.5.0109 REMARK 3 AUTHORS : MURSHUDOV,VAGIN,DODSON REMARK 3 REMARK 3 REFINEMENT TARGET : MAXIMUM LIKELIHOOD REMARK 3 REMARK 3 DATA USED IN REFINEMENT. REMARK 3 RESOLUTION RANGE HIGH (ANGSTROMS) : 1.40 REMARK 3 RESOLUTION RANGE LOW (ANGSTROMS) : 44.35 REMARK 3 DATA CUTOFF (SIGMA(F)) : NONE REMARK 3 COMPLETENESS FOR RANGE (%) : 99.79 REMARK 3 NUMBER OF REFLECTIONS : 54114 REMARK 3 REMARK 3 FIT TO DATA USED IN REFINEMENT. REMARK 3 CROSS-VALIDATION METHOD : THROUGHOUT REMARK 3 FREE R VALUE TEST SET SELECTION : RANDOM REMARK 3 R VALUE (WORKING + TEST SET) : 0.17590 REMARK 3 R VALUE (WORKING SET) : 0.17478 REMARK 3 FREE R VALUE : 0.19635 REMARK 3 FREE R VALUE TEST SET SIZE (%) : 5.1 REMARK 3 FREE R VALUE TEST SET COUNT : 2895 REMARK 3 REMARK 3 FIT IN THE HIGHEST RESOLUTION BIN. REMARK 3 TOTAL NUMBER OF BINS USED : 20 REMARK 3 BIN RESOLUTION RANGE HIGH (A) : 1.400 REMARK 3 BIN RESOLUTION RANGE LOW (A) : 1.436 REMARK 3 REFLECTION IN BIN (WORKING SET) : 3927 REMARK 3 BIN COMPLETENESS (WORKING+TEST) (%) : 99.93 REMARK 3 BIN R VALUE (WORKING SET) : 0.386 REMARK 3 BIN FREE R VALUE SET COUNT : 228 REMARK 3 BIN FREE R VALUE : 0.394 REMARK 3 REMARK 3 NUMBER OF NON-HYDROGEN ATOMS USED IN REFINEMENT. REMARK 3 PROTEIN ATOMS : 1658 REMARK 3 NUCLEIC ACID ATOMS : 0 REMARK 3 HETEROGEN ATOMS : 24 REMARK 3 SOLVENT ATOMS : 366 REMARK 3 REMARK 3 B VALUES. REMARK 3 FROM WILSON PLOT (A**2) : 19.5 REMARK 3 MEAN B VALUE (OVERALL, A**2) : 24.377 REMARK 3 OVERALL ANISOTROPIC B VALUE. REMARK 3 B11 (A**2) : -0.02 REMARK 3 B22 (A**2) : -0.08 REMARK 3 B33 (A**2) : 0.10 REMARK 3 B12 (A**2) : 0.00 REMARK 3 B13 (A**2) : 0.00 REMARK 3 B23 (A**2) : 0.00 REMARK 3 REMARK 3 ESTIMATED OVERALL COORDINATE ERROR. REMARK 3 ESU BASED ON R VALUE (A): 0.053 REMARK 3 ESU BASED ON FREE R VALUE (A): 0.054 REMARK 3 ESU BASED ON MAXIMUM LIKELIHOOD (A): 0.034 REMARK 3 ESU FOR B VALUES BASED ON MAXIMUM LIKELIHOOD (A**2): 1.745 REMARK 3 REMARK 3 CORRELATION COEFFICIENTS. REMARK 3 CORRELATION COEFFICIENT FO-FC : 0.970 REMARK 3 CORRELATION COEFFICIENT FO-FC FREE : 0.965 REMARK 3 REMARK 3 RMS DEVIATIONS FROM IDEAL VALUES COUNT RMS WEIGHT REMARK 3 BOND LENGTHS REFINED ATOMS (A): 1715 ; 0.032 ; 0.022 REMARK 3 BOND LENGTHS OTHERS (A): NULL ; NULL ; NULL REMARK 3 BOND ANGLES REFINED ATOMS (DEGREES): 2325 ; 2.683 ; 1.983 REMARK 3 BOND ANGLES OTHERS (DEGREES): NULL ; NULL ; NULL REMARK 3 TORSION ANGLES, PERIOD 1 (DEGREES): 220 ; 7.225 ; 5.000 REMARK 3 TORSION ANGLES, PERIOD 2 (DEGREES): 73 ;34.842 ;25.068 REMARK 3 TORSION ANGLES, PERIOD 3 (DEGREES): 315 ;13.156 ;15.000 REMARK 3 TORSION ANGLES, PERIOD 4 (DEGREES): 7 ;21.779 ;15.000 REMARK 3 CHIRAL-CENTER RESTRAINTS (A**3): 268 ; 0.179 ; 0.200 REMARK 3 GENERAL PLANES REFINED ATOMS (A): 1268 ; 0.017 ; 0.020 REMARK 3 GENERAL PLANES OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED CONTACTS OTHERS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 NON-BONDED TORSION OTHERS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 H-BOND (X...Y) OTHERS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 POTENTIAL METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY VDW OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY H-BOND OTHERS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION REFINED ATOMS (A): NULL ; NULL ; NULL REMARK 3 SYMMETRY METAL-ION OTHERS (A): NULL ; NULL ; NULL REMARK 3 REMARK 3 ISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 MAIN-CHAIN BOND REFINED ATOMS (A**2): 1051 ; 1.491 ; 1.500 REMARK 3 MAIN-CHAIN BOND OTHER ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 MAIN-CHAIN ANGLE REFINED ATOMS (A**2): 1704 ; 2.391 ; 2.000 REMARK 3 SIDE-CHAIN BOND REFINED ATOMS (A**2): 664 ; 3.725 ; 3.000 REMARK 3 SIDE-CHAIN ANGLE REFINED ATOMS (A**2): 615 ; 5.519 ; 4.500 REMARK 3 REMARK 3 ANISOTROPIC THERMAL FACTOR RESTRAINTS. COUNT RMS WEIGHT REMARK 3 RIGID-BOND RESTRAINTS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; FREE ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 SPHERICITY; BONDED ATOMS (A**2): NULL ; NULL ; NULL REMARK 3 REMARK 3 NCS RESTRAINTS STATISTICS REMARK 3 NUMBER OF DIFFERENT NCS GROUPS : NULL REMARK 3 REMARK 3 TLS DETAILS REMARK 3 NUMBER OF TLS GROUPS : 1 REMARK 3 REMARK 3 TLS GROUP : 1 REMARK 3 NUMBER OF COMPONENTS GROUP : 1 REMARK 3 COMPONENTS C SSSEQI TO C SSSEQI REMARK 3 RESIDUE RANGE : A 16 A 224 REMARK 3 ORIGIN FOR THE GROUP (A): 31.7140 14.4720 20.2620 REMARK 3 T TENSOR REMARK 3 T11: 0.0341 T22: 0.0174 REMARK 3 T33: 0.0140 T12: -0.0019 REMARK 3 T13: 0.0050 T23: -0.0147 REMARK 3 L TENSOR REMARK 3 L11: 2.3532 L22: 1.3054 REMARK 3 L33: 1.6884 L12: 0.4124 REMARK 3 L13: 0.1671 L23: -0.1098 REMARK 3 S TENSOR REMARK 3 S11: 0.0397 S12: 0.0348 S13: -0.0040 REMARK 3 S21: 0.0198 S22: -0.0185 S23: 0.0234 REMARK 3 S31: -0.0115 S32: 0.0149 S33: -0.0212 REMARK 3 REMARK 3 BULK SOLVENT MODELLING. REMARK 3 METHOD USED : MASK REMARK 3 PARAMETERS FOR MASK CALCULATION REMARK 3 VDW PROBE RADIUS : 1.40 REMARK 3 ION PROBE RADIUS : 0.80 REMARK 3 SHRINKAGE RADIUS : 0.80 REMARK 3 REMARK 3 OTHER REFINEMENT REMARKS: HYDROGENS HAVE BEEN ADDED IN THE REMARK 3 RIDING POSITIONS. REMARK 4 REMARK 4 2YI7 COMPLIES WITH FORMAT V. 3.30, 13-JUL-11 REMARK 100 REMARK 100 THIS ENTRY HAS BEEN PROCESSED BY PDBE ON 10-MAY-11. REMARK 100 THE PDBE ID CODE IS EBI-48257. REMARK 200 REMARK 200 EXPERIMENTAL DETAILS REMARK 200 EXPERIMENT TYPE : X-RAY DIFFRACTION REMARK 200 DATE OF DATA COLLECTION : 27-MAY-09 REMARK 200 TEMPERATURE (KELVIN) : 100 REMARK 200 PH : 7 REMARK 200 NUMBER OF CRYSTALS USED : 1 REMARK 200 REMARK 200 SYNCHROTRON (Y/N) : Y REMARK 200 RADIATION SOURCE : DIAMOND REMARK 200 BEAMLINE : I02 REMARK 200 X-RAY GENERATOR MODEL : NULL REMARK 200 MONOCHROMATIC OR LAUE (M/L) : M REMARK 200 WAVELENGTH OR RANGE (A) : 0.9796 REMARK 200 MONOCHROMATOR : NULL REMARK 200 OPTICS : NULL REMARK 200 REMARK 200 DETECTOR TYPE : CCD REMARK 200 DETECTOR MANUFACTURER : ADSC REMARK 200 INTENSITY-INTEGRATION SOFTWARE : MOSFLM REMARK 200 DATA SCALING SOFTWARE : SCALA REMARK 200 REMARK 200 NUMBER OF UNIQUE REFLECTIONS : 57073 REMARK 200 RESOLUTION RANGE HIGH (A) : 1.40 REMARK 200 RESOLUTION RANGE LOW (A) : 45.00 REMARK 200 REJECTION CRITERIA (SIGMA(I)) : 0.0 REMARK 200 REMARK 200 OVERALL. REMARK 200 COMPLETENESS FOR RANGE (%) : 99.8 REMARK 200 DATA REDUNDANCY : 4.2 REMARK 200 R MERGE (I) : 0.05 REMARK 200 R SYM (I) : NULL REMARK 200 FOR THE DATA SET : 18.30 REMARK 200 REMARK 200 IN THE HIGHEST RESOLUTION SHELL. REMARK 200 HIGHEST RESOLUTION SHELL, RANGE HIGH (A) : 1.40 REMARK 200 HIGHEST RESOLUTION SHELL, RANGE LOW (A) : 1.48 REMARK 200 COMPLETENESS FOR SHELL (%) : 99.8 REMARK 200 DATA REDUNDANCY IN SHELL : 3.9 REMARK 200 R MERGE FOR SHELL (I) : 0.39 REMARK 200 R SYM FOR SHELL (I) : NULL REMARK 200 FOR SHELL : 3.30 REMARK 200 REMARK 200 DIFFRACTION PROTOCOL: SINGLE WAVELENGTH REMARK 200 METHOD USED TO DETERMINE THE STRUCTURE: MOLECULAR REPLACEMENT REMARK 200 SOFTWARE USED: PHASER REMARK 200 STARTING MODEL: INTERNAL STRUCTURE REMARK 200 REMARK 200 REMARK: NONE REMARK 280 REMARK 280 CRYSTAL REMARK 280 SOLVENT CONTENT, VS (%): 58 REMARK 280 MATTHEWS COEFFICIENT, VM (ANGSTROMS**3/DA): 2.9 REMARK 280 REMARK 280 CRYSTALLIZATION CONDITIONS: NULL REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY REMARK 290 SYMMETRY OPERATORS FOR SPACE GROUP: I 2 2 2 REMARK 290 REMARK 290 SYMOP SYMMETRY REMARK 290 NNNMMM OPERATOR REMARK 290 1555 X,Y,Z REMARK 290 2555 -X,-Y,Z REMARK 290 3555 -X,Y,-Z REMARK 290 4555 X,-Y,-Z REMARK 290 5555 X+1/2,Y+1/2,Z+1/2 REMARK 290 6555 -X+1/2,-Y+1/2,Z+1/2 REMARK 290 7555 -X+1/2,Y+1/2,-Z+1/2 REMARK 290 8555 X+1/2,-Y+1/2,-Z+1/2 REMARK 290 REMARK 290 WHERE NNN -> OPERATOR NUMBER REMARK 290 MMM -> TRANSLATION VECTOR REMARK 290 REMARK 290 CRYSTALLOGRAPHIC SYMMETRY TRANSFORMATIONS REMARK 290 THE FOLLOWING TRANSFORMATIONS OPERATE ON THE ATOM/HETATM REMARK 290 RECORDS IN THIS ENTRY TO PRODUCE CRYSTALLOGRAPHICALLY REMARK 290 RELATED MOLECULES. REMARK 290 SMTRY1 1 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 1 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 1 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 2 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 2 0.000000 0.000000 1.000000 0.00000 REMARK 290 SMTRY1 3 -1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 3 0.000000 1.000000 0.000000 0.00000 REMARK 290 SMTRY3 3 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 4 1.000000 0.000000 0.000000 0.00000 REMARK 290 SMTRY2 4 0.000000 -1.000000 0.000000 0.00000 REMARK 290 SMTRY3 4 0.000000 0.000000 -1.000000 0.00000 REMARK 290 SMTRY1 5 1.000000 0.000000 0.000000 32.61500 REMARK 290 SMTRY2 5 0.000000 1.000000 0.000000 44.35250 REMARK 290 SMTRY3 5 0.000000 0.000000 1.000000 49.81250 REMARK 290 SMTRY1 6 -1.000000 0.000000 0.000000 32.61500 REMARK 290 SMTRY2 6 0.000000 -1.000000 0.000000 44.35250 REMARK 290 SMTRY3 6 0.000000 0.000000 1.000000 49.81250 REMARK 290 SMTRY1 7 -1.000000 0.000000 0.000000 32.61500 REMARK 290 SMTRY2 7 0.000000 1.000000 0.000000 44.35250 REMARK 290 SMTRY3 7 0.000000 0.000000 -1.000000 49.81250 REMARK 290 SMTRY1 8 1.000000 0.000000 0.000000 32.61500 REMARK 290 SMTRY2 8 0.000000 -1.000000 0.000000 44.35250 REMARK 290 SMTRY3 8 0.000000 0.000000 -1.000000 49.81250 REMARK 290 REMARK 290 REMARK: NULL REMARK 300 REMARK 300 BIOMOLECULE: 1 REMARK 300 SEE REMARK 350 FOR THE AUTHOR PROVIDED AND/OR PROGRAM REMARK 300 GENERATED ASSEMBLY INFORMATION FOR THE STRUCTURE IN REMARK 300 THIS ENTRY. THE REMARK MAY ALSO PROVIDE INFORMATION ON REMARK 300 BURIED SURFACE AREA. REMARK 350 REMARK 350 COORDINATES FOR A COMPLETE MULTIMER REPRESENTING THE KNOWN REMARK 350 BIOLOGICALLY SIGNIFICANT OLIGOMERIZATION STATE OF THE REMARK 350 MOLECULE CAN BE GENERATED BY APPLYING BIOMT TRANSFORMATIONS REMARK 350 GIVEN BELOW. BOTH NON-CRYSTALLOGRAPHIC AND REMARK 350 CRYSTALLOGRAPHIC OPERATIONS ARE GIVEN. REMARK 350 REMARK 350 BIOMOLECULE: 1 REMARK 350 AUTHOR DETERMINED BIOLOGICAL UNIT: DIMERIC REMARK 350 SOFTWARE DETERMINED QUATERNARY STRUCTURE: DIMERIC REMARK 350 SOFTWARE USED: PISA REMARK 350 TOTAL BURIED SURFACE AREA: 1820 ANGSTROM**2 REMARK 350 SURFACE AREA OF THE COMPLEX: 18970 ANGSTROM**2 REMARK 350 CHANGE IN SOLVENT FREE ENERGY: -26.5 KCAL/MOL REMARK 350 APPLY THE FOLLOWING TO CHAINS: A REMARK 350 BIOMT1 1 1.000000 0.000000 0.000000 0.00000 REMARK 350 BIOMT2 1 0.000000 1.000000 0.000000 0.00000 REMARK 350 BIOMT3 1 0.000000 0.000000 1.000000 0.00000 REMARK 350 BIOMT1 2 -1.000000 0.000000 0.000000 65.23000 REMARK 350 BIOMT2 2 0.000000 -1.000000 0.000000 0.00000 REMARK 350 BIOMT3 2 0.000000 0.000000 1.000000 0.00000 REMARK 465 REMARK 465 MISSING RESIDUES REMARK 465 THE FOLLOWING RESIDUES WERE NOT LOCATED IN THE REMARK 465 EXPERIMENT. (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 465 IDENTIFIER; SSSEQ=SEQUENCE NUMBER; I=INSERTION CODE.) REMARK 465 REMARK 465 M RES C SSSEQI REMARK 465 MET A 1 REMARK 465 PRO A 2 REMARK 465 GLU A 3 REMARK 465 GLU A 4 REMARK 465 THR A 5 REMARK 465 GLN A 6 REMARK 465 THR A 7 REMARK 465 GLN A 8 REMARK 465 ASP A 9 REMARK 465 GLN A 10 REMARK 465 PRO A 11 REMARK 465 MET A 12 REMARK 465 GLU A 13 REMARK 465 GLU A 14 REMARK 465 GLU A 15 REMARK 465 GLU A 225 REMARK 465 ARG A 226 REMARK 465 ASP A 227 REMARK 465 LYS A 228 REMARK 465 GLU A 229 REMARK 470 REMARK 470 MISSING ATOM REMARK 470 THE FOLLOWING RESIDUES HAVE MISSING ATOMS (M=MODEL NUMBER; REMARK 470 RES=RESIDUE NAME; C=CHAIN IDENTIFIER; SSEQ=SEQUENCE NUMBER; REMARK 470 I=INSERTION CODE): REMARK 470 M RES CSSEQI ATOMS REMARK 470 GLU A 16 CG CD OE1 OE2 REMARK 470 GLN A 212 CG CD OE1 NE2 REMARK 470 LYS A 224 CG CD CE NZ REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS IN SAME ASYMMETRIC UNIT REMARK 500 REMARK 500 THE FOLLOWING ATOMS ARE IN CLOSE CONTACT. REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI DISTANCE REMARK 500 O HOH A 2092 O HOH A 2093 0.91 REMARK 500 CB GLU A 178 O HOH A 2300 1.28 REMARK 500 O HOH A 2250 O HOH A 2251 1.38 REMARK 500 CG GLU A 178 O HOH A 2300 1.44 REMARK 500 O HOH A 2121 O HOH A 2122 1.46 REMARK 500 O HOH A 2346 O HOH A 2347 1.52 REMARK 500 OH TYR A 38 O HOH A 2059 1.55 REMARK 500 O HOH A 2276 O HOH A 2277 1.67 REMARK 500 OE1 GLU A 178 O HOH A 2300 1.68 REMARK 500 CE2 TYR A 38 O HOH A 2059 1.69 REMARK 500 CD GLU A 178 O HOH A 2300 1.71 REMARK 500 CZ TYR A 38 O HOH A 2059 1.79 REMARK 500 NZ LYS A 191 O HOH A 2255 1.93 REMARK 500 O HOH A 2082 O HOH A 2083 1.98 REMARK 500 O HOH A 2140 O HOH A 2142 1.99 REMARK 500 O HOH A 2087 O HOH A 2363 2.03 REMARK 500 OE2 GLU A 75 O HOH A 2166 2.04 REMARK 500 O HOH A 2310 O HOH A 2316 2.08 REMARK 500 O HOH A 2044 O HOH A 2246 2.10 REMARK 500 O HOH A 2124 O HOH A 2125 2.13 REMARK 500 O HOH A 2038 O HOH A 2057 2.14 REMARK 500 O HOH A 2001 O HOH A 2004 2.17 REMARK 500 O HOH A 2055 O HOH A 2122 2.19 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CLOSE CONTACTS REMARK 500 REMARK 500 THE FOLLOWING ATOMS THAT ARE RELATED BY CRYSTALLOGRAPHIC REMARK 500 SYMMETRY ARE IN CLOSE CONTACT. AN ATOM LOCATED WITHIN 0.15 REMARK 500 ANGSTROMS OF A SYMMETRY RELATED ATOM IS ASSUMED TO BE ON A REMARK 500 SPECIAL POSITION AND IS, THEREFORE, LISTED IN REMARK 375 REMARK 500 INSTEAD OF REMARK 500. ATOMS WITH NON-BLANK ALTERNATE REMARK 500 LOCATION INDICATORS ARE NOT INCLUDED IN THE CALCULATIONS. REMARK 500 REMARK 500 DISTANCE CUTOFF: REMARK 500 2.2 ANGSTROMS FOR CONTACTS NOT INVOLVING HYDROGEN ATOMS REMARK 500 1.6 ANGSTROMS FOR CONTACTS INVOLVING HYDROGEN ATOMS REMARK 500 REMARK 500 ATM1 RES C SSEQI ATM2 RES C SSEQI SSYMOP DISTANCE REMARK 500 O HOH A 2050 O HOH A 2233 2655 2.12 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND LENGTHS REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,2(A3,1X,A1,I4,A1,1X,A4,3X),1X,F6.3) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 RES CSSEQI ATM2 DEVIATION REMARK 500 TYR A 38 CE1 TYR A 38 CZ -0.084 REMARK 500 TYR A 38 CE2 TYR A 38 CD2 0.097 REMARK 500 GLU A 42 CD GLU A 42 OE1 -0.069 REMARK 500 ARG A 60 NE ARG A 60 CZ 0.079 REMARK 500 ASP A 157 CB ASP A 157 CG 0.181 REMARK 500 ASP A 157 CG ASP A 157 OD2 0.158 REMARK 500 TYR A 160 CD1 TYR A 160 CE1 0.096 REMARK 500 LYS A 191 CG LYS A 191 CD -0.218 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: COVALENT BOND ANGLES REMARK 500 REMARK 500 THE STEREOCHEMICAL PARAMETERS OF THE FOLLOWING RESIDUES REMARK 500 HAVE VALUES WHICH DEVIATE FROM EXPECTED VALUES BY MORE REMARK 500 THAN 6*RMSD (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,3(1X,A4,2X),12X,F5.1) REMARK 500 REMARK 500 EXPECTED VALUES PROTEIN: ENGH AND HUBER, 1999 REMARK 500 EXPECTED VALUES NUCLEIC ACID: CLOWNEY ET AL 1996 REMARK 500 REMARK 500 M RES CSSEQI ATM1 ATM2 ATM3 REMARK 500 LEU A 32 CA - CB - CG ANGL. DEV. = 14.3 DEGREES REMARK 500 TYR A 38 CB - CG - CD1 ANGL. DEV. = -4.3 DEGREES REMARK 500 TYR A 38 CG - CD2 - CE2 ANGL. DEV. = -6.7 DEGREES REMARK 500 ARG A 46 NE - CZ - NH2 ANGL. DEV. = -3.7 DEGREES REMARK 500 ASP A 54 CB - CG - OD1 ANGL. DEV. = 6.7 DEGREES REMARK 500 ASP A 54 CB - CG - OD2 ANGL. DEV. = -9.5 DEGREES REMARK 500 ASP A 57 CB - CG - OD1 ANGL. DEV. = 5.5 DEGREES REMARK 500 ASP A 57 CB - CG - OD2 ANGL. DEV. = -6.9 DEGREES REMARK 500 ARG A 60 CD - NE - CZ ANGL. DEV. = 13.5 DEGREES REMARK 500 ARG A 60 NE - CZ - NH1 ANGL. DEV. = 8.3 DEGREES REMARK 500 ARG A 87 NE - CZ - NH2 ANGL. DEV. = -4.3 DEGREES REMARK 500 ASP A 102 CB - CG - OD1 ANGL. DEV. = 6.5 DEGREES REMARK 500 LEU A 103 CB - CA - C ANGL. DEV. = -13.2 DEGREES REMARK 500 ASP A 157 CB - CG - OD2 ANGL. DEV. = 10.1 DEGREES REMARK 500 TYR A 160 CD1 - CE1 - CZ ANGL. DEV. = -5.6 DEGREES REMARK 500 ASP A 175 CB - CG - OD1 ANGL. DEV. = 5.8 DEGREES REMARK 500 ARG A 182 NE - CZ - NH1 ANGL. DEV. = 5.8 DEGREES REMARK 500 ASP A 193 CB - CG - OD1 ANGL. DEV. = 5.9 DEGREES REMARK 500 ARG A 202 NE - CZ - NH2 ANGL. DEV. = -4.7 DEGREES REMARK 500 PHE A 221 CB - CG - CD2 ANGL. DEV. = -4.9 DEGREES REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: TORSION ANGLES REMARK 500 REMARK 500 TORSION ANGLES OUTSIDE THE EXPECTED RAMACHANDRAN REGIONS: REMARK 500 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 500 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE). REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT:(10X,I3,1X,A3,1X,A1,I4,A1,4X,F7.2,3X,F7.2) REMARK 500 REMARK 500 EXPECTED VALUES: GJ KLEYWEGT AND TA JONES (1996). PHI/PSI- REMARK 500 CHOLOGY: RAMACHANDRAN REVISITED. STRUCTURE 4, 1395 - 1400 REMARK 500 REMARK 500 M RES CSSEQI PSI PHI REMARK 500 TYR A 38 111.02 -161.80 REMARK 500 ASN A 40 56.65 -90.69 REMARK 500 ALA A 124 22.73 -78.22 REMARK 500 ALA A 166 -150.91 62.40 REMARK 500 ARG A 182 137.43 -171.69 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: NON-CIS, NON-TRANS REMARK 500 REMARK 500 THE FOLLOWING PEPTIDE BONDS DEVIATE SIGNIFICANTLY FROM BOTH REMARK 500 CIS AND TRANS CONFORMATION. CIS BONDS, IF ANY, ARE LISTED REMARK 500 ON CISPEP RECORDS. TRANS IS DEFINED AS 180 +/- 30 AND REMARK 500 CIS IS DEFINED AS 0 +/- 30 DEGREES. REMARK 500 MODEL OMEGA REMARK 500 ASP A 156 ASP A 157 -131.83 REMARK 500 REMARK 500 REMARK: NULL REMARK 500 REMARK 500 GEOMETRY AND STEREOCHEMISTRY REMARK 500 SUBTOPIC: CHIRAL CENTERS REMARK 500 REMARK 500 UNEXPECTED CONFIGURATION OF THE FOLLOWING CHIRAL REMARK 500 CENTER(S) USING IMPROPER CA--C--CB--N CHIRALITY REMARK 500 FOR AMINO ACIDS AND C1'--O4'--N1(N9)--C2' FOR REMARK 500 NUCLEIC ACIDS OR EQUIVALENT ANGLE REMARK 500 M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN REMARK 500 IDENTIFIER; SSEQ=SEQUENCE NUMBER; I=INSERTION CODE REMARK 500 REMARK 500 STANDARD TABLE: REMARK 500 FORMAT: (10X,I3,1X,A3,1X,A1,I4,A1,6X,F5.1,6X,A1,10X,A1,3X,A16) REMARK 500 REMARK 500 M RES CSSEQI IMPROPER EXPECTED FOUND DETAILS REMARK 500 ASP A 156 22.8 L L OUTSIDE RANGE REMARK 500 REMARK 500 REMARK: NULL REMARK 620 REMARK 620 METAL COORDINATION REMARK 620 (M=MODEL NUMBER; RES=RESIDUE NAME; C=CHAIN IDENTIFIER; REMARK 620 SSEQ=SEQUENCE NUMBER; I=INSERTION CODE): REMARK 620 REMARK 620 COORDINATION ANGLES FOR: M RES CSSEQI METAL REMARK 620 MG A1226 MG REMARK 620 N RES CSSEQI ATOM REMARK 620 1 HOH A2117 O REMARK 620 2 HOH A3001 O 101.3 REMARK 620 3 HOH A2118 O 106.6 97.9 REMARK 620 4 HOH A3001 O 97.0 87.5 154.2 REMARK 620 5 HOH A2118 O 82.9 165.7 93.9 78.5 REMARK 620 6 HOH A2117 O 164.0 93.3 77.6 77.0 81.4 REMARK 620 N 1 2 3 4 5 REMARK 800 REMARK 800 SITE REMARK 800 SITE_IDENTIFIER: AC1 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE BZ8 A1225 REMARK 800 REMARK 800 SITE_IDENTIFIER: AC2 REMARK 800 EVIDENCE_CODE: SOFTWARE REMARK 800 SITE_DESCRIPTION: BINDING SITE FOR RESIDUE MG A1226 REMARK 900 REMARK 900 RELATED ENTRIES REMARK 900 RELATED ID: 2YI0 RELATED DB: PDB REMARK 900 STRUCTURAL CHARACTERIZATION OF 5-ARYL-4-(5-SUBSTITUTED- REMARK 900 2-4-DIHYDROXYPHENYL)-1,2,3-THIADIAZOLE HSP90 REMARK 900 INHIBITORS. REMARK 900 RELATED ID: 1OSF RELATED DB: PDB REMARK 900 HUMAN HSP90 IN COMPLEX WITH 17-DESMETHOXY-17-N,N- REMARK 900 DIMETHYLAMINOETHYLAMINO-GELDANAMYCIN REMARK 900 RELATED ID: 2BSM RELATED DB: PDB REMARK 900 NOVEL, POTENT SMALL MOLECULE INHIBITORS OF THE MOLECULAR REMARK 900 CHAPERONE HSP90 DISCOVERED THROUGH STRUCTURE-BASED REMARK 900 DESIGN REMARK 900 RELATED ID: 2WI3 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE REMARK 900 HSP90 CHAPERONE REMARK 900 RELATED ID: 2YE4 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YE5 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2BZ5 RELATED DB: PDB REMARK 900 STRUCTURE-BASED DISCOVERY OF A NEW CLASS OF HSP90 REMARK 900 INHIBITORS REMARK 900 RELATED ID: 2CCS RELATED DB: PDB REMARK 900 HUMAN HSP90 WITH 4-CHLORO-6-(4-PIPERAZIN-1-YL-1H- REMARK 900 PYRAZOL-3-YL)-BENZENE-1,2-DIOL REMARK 900 RELATED ID: 2YEI RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YEG RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 1UYI RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-(2,5-DIMETHOXY-BENZYL)-2- REMARK 900 FLUORO-9-PENT-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 1YC3 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN HSP90ALPHA COMPLEXED REMARK 900 WITHDIHYDROXYPHENYLPYRAZOLES REMARK 900 RELATED ID: 1UYF RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-(2-CHLORO-3,4,5- REMARK 900 TRIMETHOXY-BENZYL)-2-FLUORO-9-PENT-4-YLNYL-9H-PURIN REMARK 900 -6-YLAMINE REMARK 900 RELATED ID: 2YE3 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2BYI RELATED DB: PDB REMARK 900 3-(5-CHLORO-2,4-DIHYDROXYPHENYL)-PYRAZOLE-4- REMARK 900 CARBOXAMIDES AS INHIBITORS OF THE HSP90 MOLECULAR REMARK 900 CHAPERONE REMARK 900 RELATED ID: 2VCI RELATED DB: PDB REMARK 900 4,5 DIARYL ISOXAZOLE HSP90 CHAPERONE INHIBITORS: REMARK 900 POTENTIAL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER REMARK 900 RELATED ID: 2WI1 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE REMARK 900 HSP90 CHAPERONE REMARK 900 RELATED ID: 2XJX RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2FWZ RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN HSP90-ALPHA BOUND TO THE POTENT REMARK 900 WATERSOLUBLE INHIBITOR PU-H71 REMARK 900 RELATED ID: 2XDK RELATED DB: PDB REMARK 900 STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XJG RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 1UYH RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2,5-DIMETHOXY- REMARK 900 BENZYL)-2-FLUORO-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 2FWY RELATED DB: PDB REMARK 900 STRUCTURE OF HUMAN HSP90-ALPHA BOUND TO THE POTENT REMARK 900 WATERSOLUBLE INHIBITOR PU-H64 REMARK 900 RELATED ID: 1UYE RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-(2-CHLORO-3,4,5- REMARK 900 TRIMETHOXY-BENZYL)-9-PENT-4-YLNYL-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 1UYL RELATED DB: PDB REMARK 900 STRUCTURE-ACTIVITY RELATIONSHIPS IN PURINE-BASED INHIBITOR REMARK 900 BINDING TO HSP90 ISOFORMS REMARK 900 RELATED ID: 2XAB RELATED DB: PDB REMARK 900 STRUCTURE OF HSP90 WITH AN INHIBITOR BOUND REMARK 900 RELATED ID: 2YEH RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 1UY7 RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(4-METHOXY-BENZYL REMARK 900 )-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 2XHT RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XHR RELATED DB: PDB REMARK 900 STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2YEF RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2BYH RELATED DB: PDB REMARK 900 3-(5-CHLORO-2,4-DIHYDROXYPHENYL)-PYRAZOLE-4- REMARK 900 CARBOXAMIDES AS INHIBITORS OF THE HSP90 MOLECULAR REMARK 900 CHAPERONE REMARK 900 RELATED ID: 2WI5 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE REMARK 900 HSP90 CHAPERONE REMARK 900 RELATED ID: 2CDD RELATED DB: PDB REMARK 900 HUMAN HSP90 WITH 4-(4-(2,3-DIHYDRO-BENZOL(1,4) REMARK 900 DIOXIN-6-YL)-5-METHYL-1H-PYRAZOL-3-YL)-6-ETHYL- REMARK 900 BENZENE-1,3-DIOL REMARK 900 RELATED ID: 1UY9 RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-BENZO[1,3]DIOXOL-,5- REMARK 900 YLMETHYL-9-BUTYL-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 1YES RELATED DB: PDB REMARK 900 HUMAN HSP90 GELDANAMYCIN-BINDING DOMAIN, "OPEN" REMARK 900 CONFORMATION REMARK 900 RELATED ID: 1BYQ RELATED DB: PDB REMARK 900 HSP90 N-TERMINAL DOMAIN BOUND TO ADP-MG REMARK 900 RELATED ID: 1UY8 RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(3-TRIMETHOXY- REMARK 900 BENZYL)-9H-PURIN-6YLAMINE REMARK 900 RELATED ID: 2WI4 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE REMARK 900 HSP90 CHAPERONE REMARK 900 RELATED ID: 2BUG RELATED DB: PDB REMARK 900 SOLUTION STRUCTURE OF THE TPR DOMAIN FROM PROTEIN REMARK 900 PHOSPHATASE 5 IN COMPLEX WITH HSP90 DERIVED PEPTIDE REMARK 900 RELATED ID: 2UWD RELATED DB: PDB REMARK 900 INHIBITION OF THE HSP90 MOLECULAR CHAPERONE IN VITRO REMARK 900 AND IN VIVO BY NOVEL, SYNTHETIC, POTENT RESORCINYLIC REMARK 900 PYRAZOLE, ISOXAZOLE AMIDE ANALOGS REMARK 900 RELATED ID: 2YEB RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YE7 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2XHX RELATED DB: PDB REMARK 900 STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2WI7 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE REMARK 900 HSP90 CHAPERONE REMARK 900 RELATED ID: 2YEJ RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2BT0 RELATED DB: PDB REMARK 900 NOVEL, POTENT SMALL MOLECULE INHIBITORS OF THE MOLECULAR REMARK 900 CHAPERONE HSP90 DISCOVERED THROUGH STRUCTURE-BASED REMARK 900 DESIGN REMARK 900 RELATED ID: 1YER RELATED DB: PDB REMARK 900 HUMAN HSP90 GELDANAMYCIN-BINDING DOMAIN, "CLOSED" REMARK 900 CONFORMATION REMARK 900 RELATED ID: 2XDU RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2YEC RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 1UYG RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-(2,5-DIMETHOXY-BENZYL)-2- REMARK 900 FLUORO-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 2CCU RELATED DB: PDB REMARK 900 HUMAN HSP90 WITH 4-CHLORO-6-(4-(4-(4- REMARK 900 METHANESULPHONYL-BENZYL)-PIERAZIN-1-YL)-1H-PYRAZOL-3- REMARK 900 YL)-BENZENE-1,3-DIOL REMARK 900 RELATED ID: 2XDS RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XDX RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XK2 RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2XJJ RELATED DB: PDB REMARK 900 STRUCTRE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 1UYD RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2-CHLORO-3,4,5 REMARK 900 -TRIMETHOXY-BENZYL)-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 2XDL RELATED DB: PDB REMARK 900 STRUCTURE OF HSP90 WITH SMALL MOLECULE INHIBITOR BOUND REMARK 900 RELATED ID: 2WI2 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE REMARK 900 HSP90 CHAPERONE REMARK 900 RELATED ID: 1UY6 RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(3,4,5-TRIMETHOXY REMARK 900 -BENZYL)-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 2YEE RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YE2 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2VCJ RELATED DB: PDB REMARK 900 4,5 DIARYL ISOXAZOLE HSP90 CHAPERONE INHIBITORS: REMARK 900 POTENTIAL THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER REMARK 900 RELATED ID: 1YC4 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF HUMAN HSP90ALPHA COMPLEXED REMARK 900 WITHDIHYDROXYPHENYLPYRAZOLES REMARK 900 RELATED ID: 2YE9 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2C2L RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURE OF THE CHIP U-BOX E3 UBIQUITIN REMARK 900 LIGASE REMARK 900 RELATED ID: 1UYK RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 8-BENZO[1,3]DIOXOL-,5- REMARK 900 YLMETHYL-9-BUTYL-2-FLUORO-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 2CCT RELATED DB: PDB REMARK 900 HUMAN HSP90 WITH 5-(5-CHLORO-2,4-DIHYDROXY-PHENYL)- REMARK 900 4-PIPERAZIN-1-YL-2H-PYRAZOLE-3-CARBOXYLIC ACID REMARK 900 ETHYLAMIDE REMARK 900 RELATED ID: 2WI6 RELATED DB: PDB REMARK 900 ORALLY ACTIVE 2-AMINO THIENOPYRIMIDINE INHIBITORS OF THE REMARK 900 HSP90 CHAPERONE REMARK 900 RELATED ID: 1YC1 RELATED DB: PDB REMARK 900 CRYSTAL STRUCTURES OF HUMAN HSP90ALPHA COMPLEXED REMARK 900 WITHDIHYDROXYPHENYLPYRAZOLES REMARK 900 RELATED ID: 2YEA RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YE6 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YED RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 1UYC RELATED DB: PDB REMARK 900 HUMAN HSP90-ALPHA WITH 9-BUTYL-8-(2,5-DIMETHOXY- REMARK 900 BENZYL)-9H-PURIN-6-YLAMINE REMARK 900 RELATED ID: 1YET RELATED DB: PDB REMARK 900 GELDANAMYCIN BOUND TO THE HSP90 GELDANAMYCIN-BINDING REMARK 900 DOMAIN REMARK 900 RELATED ID: 2JJC RELATED DB: PDB REMARK 900 HSP90 ALPHA ATPASE DOMAIN WITH BOUND SMALL MOLECULE REMARK 900 FRAGMENT REMARK 900 RELATED ID: 2YE8 RELATED DB: PDB REMARK 900 HSP90 INHIBITORS AND DRUGS FROM FRAGMENT AND VIRTUAL REMARK 900 SCREENING REMARK 900 RELATED ID: 2YI6 RELATED DB: PDB REMARK 900 STRUCTURAL CHARACTERIZATION OF 5-ARYL-4-(5-SUBSTITUTED- REMARK 900 2-4-DIHYDROXYPHENYL)-1,2,3-THIADIAZOLE HSP90 REMARK 900 INHIBITORS. REMARK 900 RELATED ID: 2YI5 RELATED DB: PDB REMARK 900 STRUCTURAL CHARACTERIZATION OF 5-ARYL-4-(5-SUBSTITUTED- REMARK 900 2-4-DIHYDROXYPHENYL)-1,2,3-THIADIAZOLE HSP90 REMARK 900 INHIBITORS. DBREF 2YI7 A 1 229 UNP P07900 HS90A_HUMAN 1 229 SEQRES 1 A 229 MET PRO GLU GLU THR GLN THR GLN ASP GLN PRO MET GLU SEQRES 2 A 229 GLU GLU GLU VAL GLU THR PHE ALA PHE GLN ALA GLU ILE SEQRES 3 A 229 ALA GLN LEU MET SER LEU ILE ILE ASN THR PHE TYR SER SEQRES 4 A 229 ASN LYS GLU ILE PHE LEU ARG GLU LEU ILE SER ASN SER SEQRES 5 A 229 SER ASP ALA LEU ASP LYS ILE ARG TYR GLU SER LEU THR SEQRES 6 A 229 ASP PRO SER LYS LEU ASP SER GLY LYS GLU LEU HIS ILE SEQRES 7 A 229 ASN LEU ILE PRO ASN LYS GLN ASP ARG THR LEU THR ILE SEQRES 8 A 229 VAL ASP THR GLY ILE GLY MET THR LYS ALA ASP LEU ILE SEQRES 9 A 229 ASN ASN LEU GLY THR ILE ALA LYS SER GLY THR LYS ALA SEQRES 10 A 229 PHE MET GLU ALA LEU GLN ALA GLY ALA ASP ILE SER MET SEQRES 11 A 229 ILE GLY GLN PHE GLY VAL GLY PHE TYR SER ALA TYR LEU SEQRES 12 A 229 VAL ALA GLU LYS VAL THR VAL ILE THR LYS HIS ASN ASP SEQRES 13 A 229 ASP GLU GLN TYR ALA TRP GLU SER SER ALA GLY GLY SER SEQRES 14 A 229 PHE THR VAL ARG THR ASP THR GLY GLU PRO MET GLY ARG SEQRES 15 A 229 GLY THR LYS VAL ILE LEU HIS LEU LYS GLU ASP GLN THR SEQRES 16 A 229 GLU TYR LEU GLU GLU ARG ARG ILE LYS GLU ILE VAL LYS SEQRES 17 A 229 LYS HIS SER GLN PHE ILE GLY TYR PRO ILE THR LEU PHE SEQRES 18 A 229 VAL GLU LYS GLU ARG ASP LYS GLU HET BZ8 A1225 23 HET MG A1226 1 HETNAM BZ8 4-CHLORO-6-[5-(4-ETHOXYPHENYL)-1,2,3- HETNAM 2 BZ8 THIADIAZOL-4-YL BENZENE-1,3-DIOL HETNAM MG MAGNESIUM ION FORMUL 2 BZ8 C16 H13 CL N2 O3 S FORMUL 3 MG MG 2+ FORMUL 4 HOH *366(H2 O) HELIX 1 1 GLN A 23 THR A 36 1 14 HELIX 2 2 GLU A 42 ASP A 66 1 25 HELIX 3 3 PRO A 67 ASP A 71 5 5 HELIX 4 4 THR A 99 ASN A 105 1 7 HELIX 5 5 ASN A 106 THR A 109 5 4 HELIX 6 6 ILE A 110 ALA A 124 1 15 HELIX 7 7 ASP A 127 GLY A 135 5 9 HELIX 8 8 VAL A 136 LEU A 143 5 8 HELIX 9 9 GLU A 192 LEU A 198 5 7 HELIX 10 10 GLU A 199 SER A 211 1 13 SHEET 1 AA 8 VAL A 17 ALA A 21 0 SHEET 2 AA 8 SER A 169 THR A 174 -1 O PHE A 170 N PHE A 20 SHEET 3 AA 8 GLN A 159 SER A 164 -1 O ALA A 161 N ARG A 173 SHEET 4 AA 8 ALA A 145 LYS A 153 -1 O VAL A 148 N SER A 164 SHEET 5 AA 8 GLY A 183 LEU A 190 -1 O GLY A 183 N LYS A 153 SHEET 6 AA 8 THR A 88 ASP A 93 -1 O LEU A 89 N LEU A 188 SHEET 7 AA 8 ILE A 78 ASN A 83 -1 O ASN A 79 N VAL A 92 SHEET 8 AA 8 ILE A 218 LEU A 220 1 O THR A 219 N LEU A 80 LINK MG MG A1226 O HOH A2117 1555 1555 1.88 LINK MG MG A1226 O HOH A3001 1555 1555 1.94 LINK MG MG A1226 O HOH A2118 1555 2655 1.86 LINK MG MG A1226 O HOH A3001 1555 2655 2.34 LINK MG MG A1226 O HOH A2118 1555 1555 2.19 LINK MG MG A1226 O HOH A2117 1555 2655 2.40 SITE 1 AC1 14 LEU A 48 ASN A 51 ALA A 55 ASP A 93 SITE 2 AC1 14 ILE A 96 GLY A 97 MET A 98 LEU A 107 SITE 3 AC1 14 GLY A 108 PHE A 138 THR A 184 VAL A 186 SITE 4 AC1 14 HOH A2102 HOH A2213 SITE 1 AC2 3 HOH A2117 HOH A2118 HOH A3001 CRYST1 65.230 88.705 99.625 90.00 90.00 90.00 I 2 2 2 8 ORIGX1 1.000000 0.000000 0.000000 0.00000 ORIGX2 0.000000 1.000000 0.000000 0.00000 ORIGX3 0.000000 0.000000 1.000000 0.00000 SCALE1 0.015330 0.000000 0.000000 0.00000 SCALE2 0.000000 0.011273 0.000000 0.00000 SCALE3 0.000000 0.000000 0.010038 0.00000